白蛋白结合型紫杉醇联合卡铂治疗晚期初治非小细胞肺癌的临床效果分析  

Clinical Effect Analysis of Albumin-bound Paclitaxel Combined with Carboplatin in the Treatment of Advanced Non-small Cell Lung Cancer

作　　者：洪菊培 顾明[1] 曹洪刚[1] HONG Jupei;GU Ming;CAO Honggang(Department of Oncology,the Third People's Hospital of Yancheng City,Yancheng,Jiangsu Province,224000 China)

机构地区：[1]盐城市第三人民医院肿瘤内科,江苏盐城224000

出　　处：《系统医学》2021年第6期125-127,共3页Systems Medicine

摘　　要：目的探析晚期非小细胞肺癌应用白蛋白结合型紫杉醇联合卡铂治疗的临床效果。方法选取该院在2018年10月—2020年6月诊治的75例晚期初治非小细胞肺癌患者,以病理组织学检查结果为依据,将其按单双号法分为对照组(37例)与治疗组(38例)两组,对照组患者接受紫杉醇联合卡铂治疗,治疗组患者接受白蛋白结合型紫杉醇联合卡铂治疗,对比两组患者不良反应及近期治疗效果。结果治疗组有效率(36.8%)及疾病控制率(76.3%)均高于对照组,差异有统计学意义(χ^(2)=4.857、6.004,P<0.05);治疗组3~4级不良反应中中性粒细胞减少18.4%、血小板减少23.7%、贫血21.1%、关节肌痛5.3%,组间差异无统计学意义(P>0.05);治疗组中性粒细胞减少发生率92.1%,明显高于对照组,差异有统计学意义(χ^(2)=9.771,P<0.05)。结论晚期初治非小细胞肺癌患者给予白蛋白结合型紫杉醇联合卡铂治疗,不良反应耐受较强,临床治疗效果较为理想,建议临床大力推广应用。Objective To explore the clinical effects of albumin-bound paclitaxel combined with carboplatin in the treatment of advanced non-small cell lung cancer.Methods Selected 75 patients with advanced NSCLC who were diagnosed and treated in this hospital from October 2018 to June 2020.Based on the results of histopathological examination,they were divided into control groups(37 cases)and treatment group(38 cases)according to the odd and even number method,the control group received paclitaxel combined with carboplatin,and the treatment group received albumin-bound paclitaxel combined with carboplatin.The adverse reactions and short-term treatment effects of the two groups were compared.Results The effective rate(36.8%)and disease control rate(76.3%)of the treatment group were higher than those of the control group,and the difference was statistically significant(χ^(2)=4.857,6.004,P<0.05);the treatment group was moderate to grade 3 to 4 adverse reactions The neutropenia was 18.4%,thrombocytopenia was 23.7%,anemia was 21.1%,and arthralgia was 5.3%.The difference between the groups was not statistically significant(P>0.05);the incidence of neutropenia in the treatment group was 92.1%,which was significantly higher than the control group,the difference was statistically significant(χ^(2)=9.771,P<0.05).Conclusion The treatment of albumin-bound paclitaxel combined with carboplatin for patients with advanced non-small cell lung cancer treatment has a strong tolerance to side effects and a relatively satisfactory clinical treatment effect.It is recommended to be promoted and applied in clinical practice.

关 键 词：非小细胞肺癌 卡铂 紫杉醇 白蛋白结合型紫杉醇 临床效果 

分 类 号：R73[医药卫生—肿瘤]